March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal of predicting the risk of thrombosis by quantifying platelet FcγRIIa (pFCG test), announced the acceptance of its abstract titled Association Between Prognostic Implications of Platelet FCɣRIIA (PFCG) and Treatment Strategy for Myocardial Infarction at The American College of Cardiology (ACC) Scientific Sessions 2024 in Atlanta.